Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was down 5.7% on Monday following a dissappointing earnings announcement. The company traded as low as $7.20 and last traded at $7.24, with a volume of 7,370,537 shares traded. The stock had previously closed at $7.68.

The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 50.53% and a negative net margin of 48,278.23%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million.

AUPH has been the subject of a number of analyst reports. FBR & Co reissued an “outperform” rating and issued a $11.00 price target (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, March 22nd. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, April 21st. HC Wainwright cut their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 18th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 20th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, March 3rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.64.

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth about $155,000. Geode Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $187,000. Oxford Asset Management bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at $211,000. Two Sigma Securities LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $240,000. Finally, TD Asset Management Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $241,000. 29.26% of the stock is owned by hedge funds and other institutional investors.

The company’s market capitalization is $502.13 million. The firm has a 50 day moving average of $6.74 and a 200 day moving average of $5.13.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/06/17/aurinia-pharmaceuticals-inc-auph-trading-down-5-7-on-disappointing-earnings-updated-updated-updated.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.